scholarly journals The development of drug delivery system for regulating mucosal immune system for future therapy of inflammatory bowel disease

2016 ◽  
Vol 31 (3) ◽  
pp. 194-200
Author(s):  
Hiroshi Nakase ◽  
Tomoya Iida ◽  
Kei Onodera
Keyword(s):  
Drug Delivery ◽  
Inflammatory Bowel Disease ◽  
Immune System ◽  
Drug Delivery System ◽  
Delivery System ◽  
Bowel Disease ◽  
Mucosal Immune System ◽  
Inflammatory Bowel ◽  
Future Therapy

scholarly journals A New Therapeutic Approach Using a Schizophyllan-based Drug Delivery System for Inflammatory Bowel Disease

2012 ◽  
Vol 20 (6) ◽  
pp. 1234-1241 ◽  
Author(s):  
Hidetoshi Takedatsu ◽  
Keiichi Mitsuyama ◽  
Shinichi Mochizuki ◽  
Teppei Kobayashi ◽  
Kazuo Sakurai ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Inflammatory Bowel Disease ◽  
Drug Delivery System ◽  
Delivery System ◽  
Bowel Disease ◽  
Therapeutic Approach ◽  
Inflammatory Bowel

scholarly journals Inflammatory Bowel Disease: The Emergence of New Trends in Lifestyle and Nanomedicine as the Modern Tool for Pharmacotherapy

Nanomaterials ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 2460
Author(s):  
Eden Mariam Jacob ◽  
Ankita Borah ◽  
Sindhu C Pillai ◽  
D. Sakthi Kumar
Keyword(s):  
Drug Delivery ◽  
Inflammatory Bowel Disease ◽  
Immune System ◽  
Bowel Disease ◽  
Oral Delivery ◽  
Drug Delivery Systems ◽  
Genetic Defect ◽  
Delivery Systems ◽  
Conventional Drug ◽  
Inflammatory Bowel

The human intestine, which harbors trillions of symbiotic microorganisms, may enter into dysbiosis when exposed to a genetic defect or environmental stress. The naissance of chronic inflammation due to the battle of the immune system with the trespassing gut bacteria leads to the rise of inflammatory bowel disease (IBD). Though the genes behind the scenes and their link to the disease are still unclear, the onset of IBD occurs in young adults and has expanded from the Western world into the newly industrialized countries. Conventional drug deliveries depend on a daily heavy dosage of immune suppressants or anti-inflammatory drugs targeted for the treatment of two types of IBD, ulcerative colitis (UC) and Crohn’s disease (CD), which are often associated with systemic side effects and adverse toxicities. Advances in oral delivery through nanotechnology seek remedies to overcome the drawbacks of these conventional drug delivery systems through improved drug encapsulation and targeted delivery. In this review, we discuss the association of genetic factors, the immune system, the gut microbiome, and environmental factors like diet in the pathogenesis of IBD. We also review the various physiological concerns required for oral delivery to the gastrointestinal tract (GIT) and new strategies in nanotechnology-derived, colon-targeting drug delivery systems.

Dysregulation of Intestinal Mucosal Immunity: Implications in Inflammatory Bowel Disease

Physiology ◽  
2001 ◽  
Vol 16 (6) ◽  
pp. 272-277 ◽  
Author(s):  
F. Stephen Laroux ◽  
Kevin P. Pavlick ◽  
Robert E. Wolf ◽  
Matthew B. Grisham
Keyword(s):  
Inflammatory Bowel Disease ◽  
Immune System ◽  
Mucosal Immunity ◽  
Immune Regulation ◽  
Bowel Disease ◽  
Mucosal Immune System ◽  
Gut Inflammation ◽  
Inflammatory Bowel ◽  
Efficient Mechanisms

The mucosal interstitia of the intestine and colon are continuously exposed to large amounts of dietary and microbial antigens. Fortunately, the mucosal immune system has evolved efficient mechanisms to distinguish potentially pathogenic from nonpathological antigens. There are, however, situations in which this immune regulation fails, resulting in chronic gut inflammation.

scholarly journals Sparring partners in inflammatory bowel disease: Resident microbiota and the gastrointestinal mucosal immune system

2011 ◽  
Vol 33 (4) ◽  
pp. 26-31
Author(s):  
Mona Bajaj-Elliott
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Immune System ◽  
Bowel Disease ◽  
Mucosal Immune System ◽  
Inflammatory Conditions ◽  
Cellular Events ◽  
Inflammatory Bowel ◽  
Molecular Nature

Intestinal homoeostasis is a complex affair. We are just beginning to appreciate the molecular nature of the crosstalk that allows happy coexistence between the commensal resident microbiota and the gastrointestinal (GI) mucosal immune system. Both microbial and host components involved in this interplay are being increasingly identified and studied. A better understanding of these multifaceted interactions holds the key for unlocking the cellular events responsible for gut inflammatory conditions such as Crohn's disease and ulcerative colitis.

Sign in / Sign up

Export Citation Format

Share Document